Keryx Biopharma (KERX) Auryxia Phase 3 Trial Data Published in Journal of the American Society of Nephrology
Tweet Send to a Friend
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced the publication of results from its pivotal Phase 3 study evaluating ferric citrate for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
